Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: Implications for a novel adjuvant in vaccine design

Edward L. Morgan, Brandon N. Morgan, Elisabeth A. Stein, Elizabeth L. Vitrs, Marilyn L. Thoman, Sam D. Sanderson, Joy A. Phillips

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

A conformationally biased, agonist of human C5a65-74 (EP67) was assessed for its adjuvant activities in vitro and in vivo. EP67 induced the release of the inflammatory (Th1) type cytokines from C5a receptor (CD88)-bearing antigen presenting cells (APC). EP67 did not induce the release of these cytokines from splenic APCs obtained from C5a receptor knockouts (CD88-/-). Serum from mice immunized with EP67-ovalbumin (OVA) contained high OVA-specific antibody (Ab) titers [IgG1, IgG2a (IGg2c), IgG2b]. Mice receiving OVA alone produced only IgG1 Abs, indicating the ability of EP67 to induce a Th1-like Ab class switch. Spleen cell cultures from wild type mice but not CD88-/- mice showed an enhanced OVA-specific proliferative response in vitro. These results indicate the ability of EP67 to drive a Th1-mediated immune response and its potential use as a unique adjuvant.

Original languageEnglish (US)
Pages (from-to)463-469
Number of pages7
JournalVaccine
Volume28
Issue number2
DOIs
StatePublished - Dec 11 2009
Externally publishedYes

Keywords

  • Adjuvants
  • Antibodies
  • C5a
  • Vaccines

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: Implications for a novel adjuvant in vaccine design'. Together they form a unique fingerprint.

  • Cite this